CAS: 123-92-2; Isoamyl Acetate

上下游产品

CAS号123-51-3 异戊醇 | CAS号108-24-7 乙酸酐 | CAS号108-05-4 乙酸乙烯酯 | CAS号2050-95-5 diisopentyl car... | CAS号1067-33-0 二醋酸二丁基锡 | CAS号64-19-7 冰醋酸 | CAS号631-61-8 乙酸铵 | CAS号75-36-5 乙酰氯 | CAS号141-78-6 乙酸乙酯 | CAS号17586-94-6 二乙酰氧二辛基锡盐 | CAS号94-46-2 苯甲酸异戊酯 | CAS号563-45-1 异戊烯 | CAS号67-64-1 丙酮 | CAS号18037-31-5 (Oi-am)2SiCl2 | CAS号75-36-5 乙酰氯 | CAS号78-69-3 四氢芳樟醇 | CAS号79-21-0 过氧乙酸 | CAS号64-19-7 冰醋酸 | CAS号7791-25-5 磺酰氯 | CAS号541-28-6 异戊基碘

5-甲基-2-己酮置于氧气,苯甲醛体系中,用 1,2-二氯乙烷 用作溶剂,化学反应 4.0H,以38.5%的收率获得乙酸异戊酯
参考文献:用fe-Sn-O混合氧化物催化分子氧的baeyer-Villiger氧化环己酮
标题:用fe-Sn-O混合氧化物催化分子氧的baeyer-Villiger氧化环己酮
摘要:合成了fe-Sn-O混合氧化物并将其用作环己酮的baeyer-Villiger氧化的催化剂,它既显示出高催化活性,又显示出选择性.X射线粉末衍射和扫描电子显微镜表明,Fe-sn-o催化剂具有四方结构,晶粒尺寸为29.3 Nm.在一个小规模的实验(5 Mmol的环己酮)中,ε-己内酯的收率高达98.8%.在放大试验(20 Mmol的环己酮)中,环己酮的转化率和ε-己内酯的收率分别为96.7和96.5%.另外,催化剂可以重复使用五次,而催化活性没有任何大的下降.版权所有©2015 John Wiley&sons,Ltd.
Doi:10.1002/aoc.3314

专利信息

专利号:US-4938940-A
优先权日:1988-01-14
标 题:Vapor-phase method for synthesis of diamond
发明人：HIROSE YOICHI; KOMAKI KUNIO
权利人:HIROSE YOICHI; SHOWA DENKO KK
摘要:A method for vapor-phase synthesis of diamond comprises burning a raw material compound for synthesis of diamond thereby forming a combustion flame, disposing a substrate for deposition of diamond in said combustion flame, and keeping said substrate at a prescribed temperature, thereby inducing deposition of diamond on said substrate.

专利号:US-2023002312-A1
优先权日:2019-11-20
标题:A continuous flow process for the synthesis of hydroxamic acid
发明人：PIMPALE MILIND JAGANNATH; KINI PRASHANT VASANT
权利人:UPL LTD
摘要:The present invention relates to a process for the synthesis of hydroxamic acids by continuous flow process wherein said process comprising reacting alkyl ester with hydroxyl amine salt in presence of base in a microreactor system and continuously producing hydroxamic acid.

专利号:US-4284582-A
优先权日:1978-04-28
标 题 :Process for the preparation of cyclopropane derivatives, intermediates in the synthesis of pyrethroid insecticides
发明人：KAYE ALBERT E; TUCKER ALAN C
权利人:ICI LTD
摘要:Compounds of formula: wherein both groups X are chlorine, bromine or trifluoromethyl, or one X is chlorine or bromine and the other is trifluoromethyl, and Y is -CN or -COOR in which R is an alkyl group, are obtained by (A) reacting a compound of the formula: wherein X1 is chlorine or bromine, with a compound of the formula: X2C=CH-CH=C(CH3)2 in the presence of metallic copper or at least one copper salt and a base, or (B) reacting a compound of the formula: Y-CH2-CN with a compound of the formula: X2C=CH-CH=C(CH3)2 and chlorine or bromine, in the presence of at least one reducible copper salt and a base, or (C) reacting a compound of formula: X-CH2-CN with a compound of the formula: wherein X1 is chlorine or bromine, in the presence of at least one copper salt. The compounds are intermediates in the synthesis of pyrethroid insecticides.

专利号:US-3887490-A
优先权日:1970-08-27
标 题 :Process for regenerating noble metal catalyst for the synthesis of hydrogen peroxide according to the anthraquinone process
发明人：SCHREYER GERD; THEISSEN FERDINAND; WEIBERG OTTO; WEIGERT WOLFGANG
权利人:DEGUSSA
摘要:In situ regeneration of noble metal catalysts for the synthesis of hydrogen peroxide by the anthraquinone process is provided by employing as the working solution coming from the extraction or desorption step and being introduced into the hydrogenation step a solution which contains at least 250 mg/liter of hydrogen peroxide, to thereby completely regenerate the noble metal catalyst by full capacity of the hydrogenation step.

专利号:US-10905769-B2
优先权日:2015-11-13
标 题:Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
发明人：BURKE JR TERRENCE R; HYMEL DAVID T; TSUJI KOHEI
权利人:THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
摘要:The description provides novel compounds that may serve as anticancer therapeutics. The compounds of the description bind to polo-like kinases through the polo-box domain. The peptide derivatives of the description have achieved improved efficacy in biochemical assays against Plk1. Exemplary compounds of the description include macrocyclic peptidomimetics with high affinity and selectivity for polo-like kinases, which may provide the basis for a new genre of anticancer therapeutics. Other exemplary compounds of the description include bi-valent compounds with that bind to polo-like kinases through both kinase domain and polo-box domain simultaneously by incorporating additional moieties that target Plk1 kinase domain, which significantly enhances affinitity relative and may provide the basis for a new genre of anticancer therapeutics. The description also provides methods of use, methods of preparation, compositions, and kits thereof. Further, the description provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.

专利号:WO-2023122322-A1
优先权日:2021-12-24
标 题:Improved processes for the preparation of ripretinib
发明人：LUTHRA PARVEN KUMAR; SINHA CHANDRASEKHAR; AROTE NITIN DNYANESHWAR; PANDEY ANAND KUMAR; TYAGI BHUPENDRA PRAKASH; SONAR JITENDRA KAMALAKAR; JAISWAL SANJAY; MISTRY MAULIK DIPAKBHAI
权利人:TEVA PHARMACEUTICALS INT GMBH; TEVA PHARMA
摘要:The present invention relates to safe and improved processes for the preparation of substantially pure intermediates of formula Va and their use in the synthesis of Ripretinib and salts thereof.